Today’s Research Reports on Stocks to Watch: Revance Therapeutics and Adamis Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / December 6, 2017 / Shares of Revance headed higher on Tuesday after announcing successful results in a pair of phase 3 clinical trials that are evaluating its RT002 treatment for glabellar lines between eyebrows. Shares of Adamis Pharmaceuticals also soared higher after announcing earlier in the week that the company has submitted an application to the FDA to begin testing naloxone.
RDI Initiates Coverage on:
Revance Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=RVNC
Adamis Pharmaceuticals Corporation
https://rdinvesting.com/news/?ticker=ADMP
Revance Therapeutics, Inc. shares closed up 33.65% yesterday on about 8.1 million shares traded. The company hit a brand new high of $37.20 during intra-day trading and was one of the best performers in the market. The company announced promising results from a pair of phase 3 clinical trials, SAKURA 1 and SAKURA, which are evaluating the company's DaxibotulinumtoxinA for Injection (RT002) treatment for glabellar lines between the eyebrows. In both trials, RT002 showed statistically significant reduction in severity of the condition compared to the placebo. If approved by the FDA, RT002 will be the first long-acting (six neuromodulator available in the U.S. CEO Dan Browne remarked, "We are extremely pleased with these positive SAKURA top-line results, which reinforce the findings from the BELMONT Phase 2 active-comparator study. These results demonstrate it is scientifically and clinically possible to create a significantly longer-acting neuromodulator with a duration of six months, compared to three to four months observed with currently available products. We look forward to providing patients and healthcare professionals with what we believe is a new, next-generation, long-acting neuromodulator for the treatment of glabellar lines."
Access RDI's Revance Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=RVNC
Adamis Pharmaceuticals Corporation shares closed up 18.75% on Tuesday with roughly 2.3 million shares traded. The company announced earlier in the week the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to start testing naloxone, an opioid antagonist used to treat narcotic overdoses, in human patients. CEO Dr. Dennis J. Carlo commented, "Since FDA approval of our Symjepi product, we have considered other drug candidates for use with our Symject syringe injection platform. We determined to pursue an IND for naloxone due to the worsening opioid crisis. With the rapid increase in fentanyl-related deaths and the persistence of widespread opioid addiction, we believe that there is a need for additional treatment options to help combat this crisis. We are excited to be moving forward with naloxone and will continue to assess additional compounds for possible use with our injection platform."
Access RDI's Adamis Pharmaceuticals Corporation Research Report at:
https://rdinvesting.com/news/?ticker=ADMP
Our Actionable Research on Revance Therapeutics, Inc. (NASDAQ: RVNC) and Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
